Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02849496 · ClinicalTrials.gov registry record · Phase 2

Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer

A Phase 2 study of Anatomic Stage III Breast Cancer AJCC v8 and Anatomic Stage IV Breast Cancer AJCC v8, sponsored by National Cancer Institute (NCI).

Active
Registry status
Phase 2
Development phase
81
Enrollment target
20
Study locations

NCT02849496 is a Phase 2 study of Anatomic Stage III Breast Cancer AJCC v8 and Anatomic Stage IV Breast Cancer AJCC v8 that is active but no longer recruiting, run by National Cancer Institute (NCI). The registered enrollment target is 81 participants, below the 304-participant average among 84 other Anatomic Stage III Breast Cancer AJCC v8 trials with a reported enrollment target (73% lower). The trial reports 20 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02849496, a Phase 2 study of Anatomic Stage III Breast Cancer AJCC v8 and Anatomic Stage IV Breast Cancer AJCC v8, is active but no longer recruiting, sponsored by National Cancer Institute (NCI).

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
81 participants
Enrollment target
20
Study locations

Study Summary

This randomized phase II trial studies how well olaparib with or without atezolizumab work in treating patients with non-HER2-positive breast cancer that has spread to nearby tissue or lymph nodes (locally advanced), that cannot be removed by surgery (unresectable), or that has spread from where it first started (primary site) to other places in the body (metastatic). Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep cancer cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. It is not known whether giving olaparib with or without atezolizumab will work better in patients with non-HER2-positive breast cancer.

Conditions Studied

Anatomic Stage III Breast Cancer AJCC v8 Anatomic Stage IV Breast Cancer AJCC v8 Metastatic Breast Carcinoma Locally Advanced Unresectable Breast Carcinoma

Interventions

  • PROCEDURE Biospecimen Collection
  • PROCEDURE Bone Marrow Aspiration
  • PROCEDURE Bone Marrow Biopsy
  • DRUG Atezolizumab
  • PROCEDURE Biopsy Procedure

Study Locations (20)

Connecticut

  • Smilow Cancer Hospital-Derby Care Center - Derby
  • Smilow Cancer Hospital Care Center-Fairfield - Fairfield
  • Smilow Cancer Hospital Care Center - Guilford - Guilford
  • Smilow Cancer Hospital Care Center at Saint Francis - Hartford
  • Smilow Cancer Center/Yale-New Haven Hospital - New Haven
  • Yale University - New Haven
  • Smilow Cancer Hospital-Orange Care Center - Orange
  • Smilow Cancer Hospital-Torrington Care Center - Torrington
  • Smilow Cancer Hospital Care Center-Trumbull - Trumbull
  • Smilow Cancer Hospital-Waterbury Care Center - Waterbury

California

  • UC San Diego Moores Cancer Center - La Jolla
  • University of California Davis Comprehensive Cancer Center - Sacramento
  • UC San Diego Medical Center - Hillcrest - San Diego
  • UCSF Medical Center-Mount Zion - San Francisco

Florida

  • Mayo Clinic in Florida - Jacksonville
  • Moffitt Cancer Center-International Plaza - Tampa
  • Moffitt Cancer Center - Tampa

Arizona

  • Mayo Clinic Hospital in Arizona - Phoenix
  • Mayo Clinic in Arizona - Scottsdale

Colorado

  • UCHealth University of Colorado Hospital - Aurora

Trial Details

FieldValue
Enrollment Target 81 participants
Start Date 2017-03-30
Est. Completion 2026-08-31
Phase Phase 2

Sponsor

National Cancer Institute (NCI)

3,257 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02849496

The ClinicalTrials.gov registry entry for NCT02849496 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 81 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 304-participant average among 84 other Anatomic Stage III Breast Cancer AJCC v8 trials with a reported enrollment target (73% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Anatomic Stage III Breast Cancer AJCC v8 appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.

NCT02849496 reports 20 study locations spanning 5 distinct geographic areas - top geographies include Connecticut, California, Florida.

Frequently Asked Questions

What is clinical trial NCT02849496 about?

NCT02849496 is a clinical study titled "Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer". This randomized phase II trial studies how well olaparib with or without atezolizumab work in treating patients with non-HER2-positive breast cancer that has spread to nearby tissue or lymph nodes (locally advanced), that cannot be removed by surgery (unresectable), or that has spread from where it ...

What is the current status of trial NCT02849496?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 81 participants. The study started on 2017-03-30. Estimated completion is 2026-08-31.

What conditions does trial NCT02849496 study?

This clinical trial studies the following conditions: Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Locally Advanced Unresectable Breast Carcinoma.

What interventions are being tested in trial NCT02849496?

The interventions under investigation include: Biospecimen Collection (PROCEDURE), Bone Marrow Aspiration (PROCEDURE), Bone Marrow Biopsy (PROCEDURE), Atezolizumab (DRUG), Biopsy Procedure (PROCEDURE).

Who is sponsoring clinical trial NCT02849496?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02849496 being conducted?

This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Anatomic Stage III Breast Cancer AJCC v8

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Anatomic Stage III Breast Cancer AJCC v8

All registered trials for this condition

Anatomic Stage IV Breast Cancer AJCC v8

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.